S&P Futures
4,079.25 -5.00 (-0.12%) Dow Futures
34,000.00 -46.00 (-0.14%) Nasdaq Futures
12,208.75 -13.50 (-0.11%) Russell 2000 Futures
1,916.10 -3.40 (-0.18%) Crude Oil
80.36 +0.68 (+0.85%) Gold
1,944.80 -0.80 (-0.04%)
Kinnate Biopharma Inc. (KNTE)
After hours:
Chart Events
Performance Outlook
| Previous Close | 7.14 |
| Open | 7.15 |
| Bid | 2.98 x 1200 |
| Ask | 9.50 x 1000 |
| Day's Range | 7.06 - 7.65 |
| 52 Week Range | 5.17 - 15.86 |
| Volume | |
| Avg. Volume | 122,796 |
| Market Cap | 323.286M |
| Beta (5Y Monthly) | -0.15 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.27 |
| Earnings Date | Mar 27, 2023 - Mar 31, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.14 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for KNTE
Related Research
- Kinnate Biopharma Inc.Daily – Vickers Top Buyers & Sellers for 06/24/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat7 months agoArgus Research
- GlobeNewswire
Kinnate Biopharma Inc. Adds Global Business and Oncology Expertise to Board of Directors with Appointment of Jill DeSimone as Independent Director
SAN FRANCISCO and SAN DIEGO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its board of directors has appointed a new independent director, Jill DeSimone, who will join effective March 1, 2023. Ms. DeSimone brings more than forty years of global business expertise in life sciences to Kinnate’s board of directors. Dean J. Mitchell, chairman of the Kinnate board of directors, commented, “I am h
- GlobeNewswire
Kinnate Biopharma Inc. to Present Trials in Progress Poster for its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers Symposium
SAN FRANCISCO and SAN DIEGO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced the poster presentation of the design and rationale of a Phase 1 trial-in-progress (KN-4802, NCT05242822) evaluating the Company’s investigational pan-FGFR inhibitor, KIN-3248, at two upcoming American Society of Clinical Oncology (ASCO)-related conferences. KIN-3248 is an irreversible, small molecule pan-FGFR inhibitor des
- Simply Wall St.
We're Not Very Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
